- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
21 result(s) found for: Lactoferrin.
Displaying page 1 of 2.
EudraCT Number: 2012-004260-22 | Sponsor Protocol Number: ELFIN01 | Start Date*: 2013-08-28 |
Sponsor Name:University of Oxford | ||
Full Title: A multi-centre randomised placebo-controlled trial of prophylactic enteral lactoferrin supplementation to prevent late-onset invasive infection in very preterm infants. | ||
Medical condition: Late onset invasive infection in very preterm infants | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012703-25 | Sponsor Protocol Number: PHSU02 | Start Date*: 2009-11-03 | |||||||||||
Sponsor Name:Pergamum AB | |||||||||||||
Full Title: A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery. | |||||||||||||
Medical condition: Patients with flexor tendon injuries in zone I or II that are admitted to the respective site will be considered for inclusion and informed about the study. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005702-49 | Sponsor Protocol Number: 2007017 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Procter & Gamble Pharmaceuticals | |||||||||||||
Full Title: A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to C... | |||||||||||||
Medical condition: Mildly-to-Moderately Active Ulcerative Colitis in Children and Adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000100-20 | Sponsor Protocol Number: 1368-0004 | Start Date*: 2017-06-06 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC) | |||||||||||||
Medical condition: Active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000891-13 | Sponsor Protocol Number: STW5-II/212-D-12-II-F;IMP17155 | Start Date*: 2014-07-21 |
Sponsor Name:Steigerwald Arzneimittelwerk GmbH | ||
Full Title: A randomised, double-blind, placebo-controlled multi-centre study to investigate the effectiveness and safety of STW5-II as add-on treatment for induction of remission in patients with mild to mode... | ||
Medical condition: Ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-011621-14 | Sponsor Protocol Number: CAIN457A2202E1 | Start Date*: 2009-11-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease | |||||||||||||
Medical condition: Moderate to severe Crohn's disease (CDAI ≥ 220 and ≤450) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022760-12 | Sponsor Protocol Number: CNTO1275CRD3003 | Start Date*: 2011-09-13 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Seve... | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) CZ (Completed) IS (Completed) IE (Completed) FR (Completed) HU (Completed) NL (Completed) DK (Completed) ES (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022758-18 | Sponsor Protocol Number: CNTO1275CRD3001 | Start Date*: 2011-08-24 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severe... | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) CZ (Completed) IS (Completed) IE (Completed) ES (Completed) DK (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013890-16 | Sponsor Protocol Number: P06120 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:GEDII - Grupo de Estudo da Doença inflamatória Intestinal | |||||||||||||
Full Title: Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients | |||||||||||||
Medical condition: This national, multi-centre, open-label pilot study will assess the histologic remission in patients with moderate to severe active ulcerative colitis under infliximab treatment who have had an ina... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003123-38 | Sponsor Protocol Number: RPC01-202 | Start Date*: 2012-12-11 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY... | |||||||||||||
Medical condition: Moderately to severely active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) GR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019970-33 | Sponsor Protocol Number: CKRP203A2201 | Start Date*: 2010-11-11 | |||||||||||
Sponsor Name:Novartis Services AG | |||||||||||||
Full Title: A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ul... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) BE (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001956-22 | Sponsor Protocol Number: CNTO1275CRD1001 | Start Date*: 2017-01-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Double-blind Pharmacokinetic study of Ustekinumab in Pediatric Subjects with Moderately to Severely Active Crohn's Disease | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) PL (Completed) FR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022759-42 | Sponsor Protocol Number: CNTO1275CRD3002 | Start Date*: 2011-08-29 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severe... | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) HU (Completed) IS (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002833-13 | Sponsor Protocol Number: AMT-101-203 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Sev... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003629-13 | Sponsor Protocol Number: PROFIT | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: A Prospective, randomised placebo controlled feasibility trial of Faecal Microbiotica Transplantation in cirrhosis | |||||||||||||
Medical condition: Cirrhosis of the liver | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011608-51 | Sponsor Protocol Number: MCA111407 | Start Date*: 2009-08-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients wit... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000048-73 | Sponsor Protocol Number: AMT-101-201 | Start Date*: 2020-09-24 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis | |||||||||||||
Medical condition: Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000634-21 | Sponsor Protocol Number: 64304500CRD2001 | Start Date*: 2016-11-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Cro... | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004222-25 | Sponsor Protocol Number: AB11003 | Start Date*: 2013-11-26 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 4-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the... | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) SK (Prohibited by CA) GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023986-23 | Sponsor Protocol Number: LF-0802 | Start Date*: 2011-05-27 | |||||||||||
Sponsor Name:Agennix Incorporated | |||||||||||||
Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
